Eirgenix, Inc.

Eirgenix, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

EirGenix is a contract development and manufacturing organization that provides high-quality and cost-effective service. We support our clients in the development, analytical testing, and cGMP manufacturing of biopharmaceuticals from pre-clinical to commercial manufacturing. EirGenix also specializes in the development of biologics, specializing in the development of biosimilars. Our Services: - Cell Line Development (mammalian/microbial systems) - Process Development and Process Optimization - Analytical Services and Quality Control - cGMP Manufacturing (mammalian/microbial systems) - Taiwan FDA inspected/approved - Japan PMDA inspected/approved - U.S. FDA inspection pending (June 2022) - EMA inspection pending (2022-2023) - Antibody-Drug Conjugate (ADC) Development and Manufacturing

Company Details

Employees
229
Founded
-
Address
101, Lane 169, Kangning St., Xizhi Dist,, New Taipei City,22180,taiwan, Province Of China
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New Taipei City
Looking for a particular Eirgenix, Inc. employee's phone or email?

Eirgenix, Inc. Questions

News

EG12014 Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers - OncLive

EG12014 Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers OncLive

EirGenix and Sandoz win EU approval for Herceptin biosimilar - Pharmaceutical Technology

EirGenix and Sandoz win EU approval for Herceptin biosimilar Pharmaceutical Technology

Sandoz and EirGenix make deal for trastuzumab biosimilar - Generics and Biosimilars Initiative

Sandoz and EirGenix make deal for trastuzumab biosimilar Generics and Biosimilars Initiative

EirGenix's comprehensive CDMO services strengthening Taiwan’s position in the global biopharmaceutical landscape - BioSpectrum Asia

EirGenix's comprehensive CDMO services strengthening Taiwan’s position in the global biopharmaceutical landscape BioSpectrum Asia

EirGenix Looks For Partner As Pertuzumab Passes Phase I - Citeline News & Insights

EirGenix Looks For Partner As Pertuzumab Passes Phase I Citeline News & Insights

Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA - Novartis

Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA Novartis

Eirgenix Protein Drug Production Plant, Zhubei, Taiwan - Pharmaceutical Technology

Eirgenix Protein Drug Production Plant, Zhubei, Taiwan Pharmaceutical Technology

Clarity expands pipeline in breast cancer with Cu-64/67 SAR-trastuzumab - BiotechDispatch

Clarity expands pipeline in breast cancer with Cu-64/67 SAR-trastuzumab BiotechDispatch

Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors - Novartis

Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors Novartis

Top Eirgenix, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant